Diagnosis and treatment of peripartum haemorrhage, consensus of the interdisciplinary working group by the modified ACCORD method

Czech version

Authors: Vladimír Černý- ^7-13; Antonín Pařízek ²³; Jan Bláha ¹; Jan Blatný- ^2-6; Petr Dulíček ¹⁴; Jaromír Gumulec ¹⁵; Petr Janků ^16,17; Marian Kacerovský ¹⁸; Petr Křepelka ^19,20; Marek Ubušký ²¹; Jitka Mannová ²²; Dagmar Seidlová ^2,24; Ondřej Šimetka ²⁵; Petr Štourač ^2,26,27
Authors‘ workplace: Klinika anesteziologie, resuscitace a intenzivní medicíny 1. LF UK a VFN v Praze ¹; Lékařská fakulta, MU, Brno ²; Oddělení dětské hematologie a bio chemie, FN Brno ³; Katedra pediatrie, IPVZ Praha ⁴; Oddělení hematologie a transfuziologie, Nemocnice Bory Bratislava, Slovenská republika ⁵; Klinika dětské onkologie a hematologie, NÚDCH Bratislava, Slovenská republika ⁶; Klinika anesteziologie, perioperační a intenzivní medicíny, Masarykova nemocnice a Univerzita J. E. Purkyně v Ústí nad Labem ⁷; Národní institut kvality a excelence zdravotnictví, ÚZIS ČR, Praha ⁸; Klinika anesteziologie a resuscitace 3. LF UK a FNKV Praha ⁹; Klinika anesteziologie, resuscitace a intenzívní medicíny LF UK a FN Hradec Králové ¹⁰; Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University Halifax, Canada ¹¹; Ústav klinických oborů a bio medicíny, TU v Liberci ¹²; Fakulta sociálních věd a zdravotnictví, Univerzita Filozofa Konštantína Filozofa v Nitře, Slovenská republika ¹³; IV. interní hematologická klinika LF UK a FN Hradec Králové ¹⁴; Klinika hematoonkologie LF OU a FN Ostrava ¹⁵; Gynekologicko-porodnická klinika LF MU a FN Brno ¹⁶; Ústav zdravotnických studií, Lékařská fakulta, MU, Brno ¹⁷; Centrum bio medicínského výzkumu, FN Hradec králové ¹⁸; Ústav pro péči o matku a dítě, Praha ¹⁹; 3. LF UK, Praha ²⁰; Porodnicko-gynekologická klinika LF UP a FN Olomouc ²¹; Anesteziologicko-resuscitační oddělení, Nemocnice Havlíčkův Brod ²²; Klinika gynekologie, porodnictví a neonatologie 1. LF UK a VFN v Praze ²³; II. anesteziologicko-resuscitač ní oddělení, FN Brno ²⁴; Gynekologicko-porodnická klinika LF OU a FN Ostrava ²⁵; Klinika dětské anesteziologie a resuscitace FN Brno ²⁶; Ústav simulační medicíny, Lékařská fakulta, MU, Brno ²⁷
Published in: Ceska Gynekol 2025; 90(1): 72-89
Category: Summary of Recommendations
doi: https://doi.org/10.48095/cccg202572

Overview

Summary of recommendations

Preventive measures and procedures

We recommend monitoring of blood loss in women with risk factors for PPH during labor using calibrated blood collectors or their equivalents.

(Good Clinical Practice)

We recommend that women with significant risk factors for PPH (e.g., placenta acrreta spectrum or hematologic disorders requiring consultative hematologic care) deliver in a perinatal intensive care center or perinatal intermediate care center.

(Good Clinical Practice)

We recommend formulating a plan of care in collaboration with a multidisciplinary team at a reasonable time prior to delivery for patients at high risk of PPH.

(Good Clinical Practice)

We recommend treating anemia antepartally. Pregnant women should be given iron supplements if the haemoglobin level falls to < 110 g/L in the 1^st trimester or < 105 g/L at 28 weeks of pregnancy.

(Good Clinical Practice)

We suggest considering parenteral iron administration in women with sideropenic anemia unresponsive to oral iron supplementation. The cause of anemia should be identified as soon as possible after termination of pregnancy.

(Weak recommendation)

If the baby adapts well, we do not recommend cord ligation in less than 1 min.

(Strong recommendation)

In all vaginal deliveries, we recommend prophylactic administration of uterotonics in the third postpartum period after the delivery of the baby and cord ligation to reduce the risk of PPH. The first-choice drug is oxytocin.

(Strong recommendation)

If the third stage of labor has not been actively managed, we suggest that uterine massage and controlled umbilical cord traction be considered to shorten the duration of the third stage of labor and to reduce blood loss during vaginal delivery, if performed by a qualified healthcare professional.

(Weak recommendation)

We recommend the administration of uterotonics to prevent the development of PPH in women after the delivery of a child by caesarean section and umbilical cord ligation.

(Strong recommendation)

We suggest considering carbetocin administration in women at increased risk of PPH.

(Weak recommendation)

We recommend a single-dose administration of tranexamic acid (TXA) in women at increased risk of PPH undergoing a caesarean section. Clinical note: The use of TXA prior to the caesarean section is not explicitly stated in the product's SPC. A recent meta-analysis states the most common dosage to be 1 g i.v.

(Strong recommendation)

Organization of care

We recommend that every health care facility with an OB/GYN unit should have the PPH management protocol (guided document is not specific or really used at all, I am not sure if my suggestion is sufficient) defining the organizational and professional procedure for PPH situations.

(Good Clinical Practice)

We recommend that the PPH management protocol (i.e. the crisis action plan) should clearly define the organizational and professional roles of the individual members of the crisis team in the event of PPH (non-medical staff), obstetrician, anesthetist, hematologist, etc.) and define the minimum scope of equipment for the care of patients with PPH.

(Good Clinical Practice)

We recommend regular simulation training of PPH crisis by the entire crisis team with a subsequent debriefing or its formalized equivalent.

(Good Clinical Practice)

We recommend defining quality indicators for the diagnosis and treatment of PPH and their formalized evaluation at regular intervals, at least once a year.

(Good Clinical Practice)

Diagnostic and treatment procedure at PPH

When hypotonia or atony of the uterus is found, we recommend using a structured procedure.

(Good Clinical Practice)

At departments with an option of endovascular interventions, we suggest considering the preferential use of radiological interventional methods (selective pelvic artery embolization) in cases of PPH due to uterine hypotonia or atony, if the current clinical context allows it.

(Weak recommendation)

For all stages of PPH development, we recommend a pre-transfusion examination. In addition to standard laboratory tests, point-of-care-testing methods, especially viscoelastic methods, are preferred to assess the current coagulation status.

(Good Clinical Practice)

Each obstetric unit should ensure a sufficient stock of blood products and blood derivatives for their immediate availability 24/7 in collaboration with the transfusion department and the inpatient pharmacy. In case of PPH development, we recommend securing initial availability of 4 units of plasma (solvent/detergent-treated plasma is preferred), 4 units of erythrocytes and 6 g of fibrinogen. We consider 8 g to be a minimum supply of fibrinogen and additional 8 g should be available within 1 h.

(Good Clinical Practice)

We recommend the initiation of immediate fluid resuscitation in all patients with PPH. We recommend the use of balanced crystalloid solutions to initiate fluid resuscitation.

(Strong recommendation)

We propose considering the use of synthetic colloid solutions containing gelatin when hemodynamic goals of fluid resuscitation have not been achieved or are not being achieved using crystalloid solutions and when a fluid deficit persists.

(Weak recommendation)

Until the source of bleeding is controlled, we recommend aiming for a systolic blood pressure in a range of 80–90 mmHg in patients with PPH.

(Strong recommendation)

We recommend the use of vasopressors as soon as possible in PPH when target arterial blood pressure values cannot be reached by ongoing fluid resuscitation.

(Strong recommendation)

We recommend cooperation with a hematologist in the diagnosis and treatment of coagulopathy in PPH unresponsive to standard therapies.

(Good Clinical Practice)

In addition to the above-mentioned panel laboratory tests (at least KO, aPTT, fibrinogen), we also recommend using viscoelastic methods (ROTEM, TEG) to identify the type of coagulation disorder in PPH, to monitor it and for targeted treatment of hemostasis disorders.

(Strong recommendation)

To achieve/restore the efficacy of endogenous hemostatic mechanisms and coagulation support therapies, we recommend the maximum possible correction of hypothermia, acidosis and ionized calcium levels.

(Strong recommendation)

Early initiation of all available procedures to prevent hypothermia and maintain or achieve normothermia is recommended.

(Strong recommendation)

It is recommended monitoring and maintaining ionized calcium levels within the normal range when administering transfusion products.

Preferably, calcium chloride should be administered for correction.

(Strong recommendation)

Fibrinogen replacement is recommended in patients with PPH when fibrinogen levels fall to < 2 g/L and/or when there is a functional fibrinogen deficiency detected by viscoelastic methods and/or when there is a reasonable clinical assumption of fibrinogen deficiency even without knowledge of fibrinogen levels. We recommend a minimum of 4 g of fibrinogen as an initial dose in PPH.

(Strong recommendation)

It is recommended to administer tranexamic acid (TXA) at an initial dose of 1 g i.v. as soon as possible after the onset of PPH. An identical dose may be repeated (after 30 min at the earliest) if bleeding continues and if hyperfibrinolysis is demonstrated and/or if hyperfibrinolysis is highly likely in the current clinical context.

(Strong recommendation)

We do not recommend further administration of TXA in patients with PPH after bleeding control has been achieved.

(Strong recommendation)

We recommend administration of plasma at a dose of 15–20 mL/kg in PPH conditions where coagulopathy of a different etiology than fibrinogen deficiency is suspected and/or abnormal coagulation test results are present, and where the results do not reliably identify the predominant mechanism of the coagulation disorder and its targeted correction.

(Strong recommendation)

We recommend the administration of prothrombin complex factors (PCC) in patients with PPH where there is a laboratory evidence of a deficiency of PCC factors. We do not recommend routine administration of PCC in patients with PPH.

(Strong recommendation)

We suggest considering administration of rFVIIa before making a decision on an endovascular or a surgical intervention.

(Weak recommendation)

In patients with PPH, we recommend administration of erythrocyte blood products to achieve a target hemoglobin value in the range 70–80 g/L.

(Strong recommendation)

In patients with PPH, we recommend platelet administration to achieve a target value of at least 50 × 10⁹/L and/or when platelet function impairment is suspected or demonstrated.

(Strong recommendation)

We do not recommend routine measurement of antithrombin III levels in patients with PPH.

(Strong recommendation)

We do not recommend routine antithrombin III replacement in patients with PPH.

(Strong recommendation)

We recommend initiating pharmacological prophylaxis for thromboembolic disease as soon as possible after control of the source of PPH is achieved. We recommend initiating mechanical thromboprophylaxis (intermittent pneumatic compression or elastic stockings) as soon as the clinical condition permits.

(Strong recommendation)

Keywords:

recombinant factor VIIa – peripartum hemorrhage – pressure and subpressure intrauterine devices – hemostatic intrauterine devices – viscoelastic methods – uterotonic prophylaxis – crisis management – hemorrhage prevention – simulation medicine

Sources

1. Pařízek A, Binder T, Bláha J et al. Diagnostika a léčba peripartálního život ohrožujícího krvácení. Ceska Gynekol 2018; 83 (2): 150–157.

2. Gattrell WT, Logullo P, van Zuuren EJ et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 2024; 21 (1): e1004326. doi: 10.1371/journal.pmed.1004326.

3. Guideline Development Tool. 2024 [online]. Available from: https: //gdt.gradepro.org/app/#organizations.

4. Kramer MS, Berg C, Abenhaim H et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013; 209 (5): 449.e1–449.e7. doi: 10.1016/j.ajog.2013.07.007.

5. Patek K, Friedman P. Postpartum hemorrhage-epidemiology, risk factors, and causes. Clin Obstet Gynecol 2023; 66 (2): 344–356. doi: 10.1097/GRF.00000000000000782.

6. Rath WH. Postpartum hemorrhage – update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand 2011; 90 (5): 421–428. doi: 10.1111/j.1600-0412.2011.01107.x.

7. Ginnane JF, Aziz S, Sultana S et al. The cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: a systematic review of economic evaluations. PLoS Med 2024; 21 (9): e1004461. doi: 10.1371/journal.pmed.1004461.

8. Glonnegger H, Glenzer MM, Lancaster L et al. Prepartum anemia and risk of postpartum hemorrhage: a meta-analysis and brief review. Clin Appl Thromb Hemost 2023; 29: 10760296231214536. doi: 10.1177/107602962 31214536.

9. Radhika AG, Sharma AK, Perumal V et al. Parenteral versus oral iron for treatment of iron deficiency anaemia during pregnancy and post-partum: a systematic review. J Obstet Gynaecol India 2019; 69 (1): 13–24. doi: 10.1007/s13224- 018-1191-8.

10. Optimal timing of cord clamping for the prevention of iron deficiency anaemia in infants. 2024 [online]. Available from: https: //www.who.int/tools/elena/interventions/cord-clamping.

11. Seidler AL, Libesman S, Hunter KE et al. Short, medium, and long deferral of umbilical cord clamping compared with umbilical cord milking and immediate clamping at preterm birth: a systematic review and network meta-analysis with individual participant data. Lancet 2023; 402 (10418): 2223–2234. doi: 10.1016/ S0140-6736 (23) 02469-8.

12. Parry Smith WR, Papadopoulou A, Thomas E et al. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev 2020; 11 (11): CD012754. doi: 10.1002/14651858.CD012757.pub2.

13. Onwochei DN, Owolabi A, Singh PM et al. Carbetocin compared with oxytocin in non-elective Cesarean delivery: a systematic review, meta-analysis, and trial sequential analysis of randomized-controlled trials. Can J Anaesth 2020; 67 (11): 1524–1534. doi: 10.1007/s126 30-020-01779-1.

14. Oladapo OT, Okusanya BO, Abalos E et al. Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour. Cochrane Database Syst Rev 2020; 11 (11): CD009332. doi: 10.1002/14651858.CD009332.pub4.

15. Ginnane JF, Aziz S, Sultana S et al. The cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: a systematic review of economic evaluations. PLoS Med 2024; 21 (9): e1004461. doi: 10.1371/journal.pmed.1004461.

16. Torloni MR, Siaulys M, Riera R et al. Timing of oxytocin administration to prevent post-partum hemorrhage in women delivered by cesarean section: a systematic review and metanalysis. PLoS One 2021; 16 (6): e0252491. doi: 10.1371/journal.pone.0252491.

17. Kalafat E, Gokce A, O’Brien P et al. Efficacy of carbetocin in the prevention of postpartum hemorrhage: a systematic review and Bayesian meta-analysis of randomized trials. J Matern Neonatal Med 2021; 34 (14): 2303–2316. doi: 10.1080/14767058.2019.1664463.

18. Ai W, Zeng Y, Ma Y et al. Side-effects of carbetocin to prevent postpartum hemorrhage: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res Perspect 2021; 9 (2): e00745. doi: 10.1002/prp 2.745.

19. Jaffer D, Singh PM, Aslam A et al. Preventing postpartum hemorrhage after cesarean delivery: a network meta-analysis of available pharmacologic agents. Am J Obstet Gynecol 2022; 226 (3): 347–365. doi: 10.1016/ j.ajog.2021.08.060.

20. Kadirogullari P, Aslan Cetin B, Goksu M et al. The effect of uterine massage after vaginal delivery on the duration of placental delivery and amount of postpartum hemorrhage. Arch Gynecol Obstet 2024; 309 (6): 2689–2695. doi: 10.1007/s00404-023-07211-5.

21. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2013; 2013 (7): CD006431. doi: 10.1002/14651858.CD006431.pub3.

22. Heesen M, Orbach-Zinger S. Optimal uterotonic management. Best Pract Res Clin Anaesthesiol 2022; 36 (1): 135–155. doi: 10.1016/ j.bpa.2022.02.002.

23. Chao YS, McCormack S. Carbetocin for the prevention of post-partum hemorrhage: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Helth 2019.

24. Shakur H, Roberts I, Fawole B et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105–2116. doi: 10.1016/S0140-67 36 (17) 30638-4.

25. Figo. Joint statement of recommendation for the use of tranexamic acid for the treatment of postpartum haemorrhage. 2024 [online]. Available from: https: //www.figo.org/joint-statement-recommendation-tranexamic-acid-treatment-pph.

26. Chipman ML, Schreiber CM, Fey JM et al. Engagement across professions: a mixed methods study of debriefing after interprofessional team training. Simul Healthc 2024; 19 (4): 228–234. doi: 10.1097/SIH.00000000000 00736.

27. Cheng A, Grant V, Eppich W. The PEARLS debriefing checklist – optimal use for faculty development. Simul Healthc 2024; 19 (4): 265–266. doi: 10.1097/SIH.0000000000000816.

28. Fanning RM, Gaba DM. The role of debriefing in simulation-based learning. Simul Healthc 2007; 2 (2): 115–125. doi: 10.1097/SIH.0b013e 3180315539.

29. D’Alton ME, Rood KM, Smid MC et al. Intrauterine vacuum-induced hemorrhage-control device for rapid treatment of postpartum hemorrhage. Obstet Gynecol 2020; 136 (5): 882–891. doi: 10.1097/AOG.0000000000004138.

30. The JADA System. Postpartum hemorrhage Control. 2024 [online]. Available from: https: //www.thejadasystem.com/.

31. Storms J, Van Calsteren K, Lewi L et al. Interventional radiology for prevention and management of postpartum haemorrhage: a single centre retrospective cohort study. Arch Gynecol Obstet 2024. doi: 10.1007/s00404-024-07 595-y.

32. Kurup M, Bidarahalli S, Sadananda A et al. Role of interventional radiology in obstetrics and gynaecology: a clinical review of an experience in a quaternary care centre. Arch Gynecol Obstet 2024; 309 (2): 581–588. doi: 10.1007/s00404-023-07273-5.

33. Gorsi U, Bansal A, Chaluvashetty SB et al. Interventional radiology in the management of uncommon causes of obstetric haemorrhage. Eur J Radiol 2021; 134: 109415. doi: 10.1016/ j.ejrad.2020.109415.

34. Kellie FJ, Wandabwa JN, Mousa HA et al. Mechanical and surgical interventions for treating primary postpartum haemorrhage. Cochrane database Syst Rev 2020; 7 (7): CD013663. doi: 10.1002/14651858.CD013663.

35. Rossaint R, Afshari A, Bouillon B et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care 2023; 27 (1): 80. doi: 10.1186/s13054-023-04327-7.

36. Schol PB, de Lange N, Henskens Y et al. Restrictive versus liberal fluid administration strategy (REFILL study) in postpartum hemorrhage and its effects on thromboelastometry (ROTEM®) values: a randomized, controlled trial. J Int Med Res 2023; 51 (8): 3000605231171007. doi: 10.1177/03000605231171007.

37. Henriquez DD, Bloemenkamp KW, Loeff RM et al. Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: a nationwide cohort study. Eur J Obstet Gynecol Reprod Biol 2019; 235: 49–56. doi: 10.1016/ j.ejogrb.2019.01.027.

38. Ramesh GH, Uma JC, Farhath S. Fluid resuscitation in trauma: what are the best strategies and fluids? Int J Emerg Med 2019; 12 (1): 38. doi: 10.1186/s12245-019-0253-8.

39. Gruneberg D, Hofer S, Schöchl H et al. Comparison of two biscoelastic testing devices in a parturient population. J Clin Med 2024; 13 (3): 692. doi: 10.3390/jcm13030692.

40. Bell SF, de Lloyd L, Preston N et al. Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays. J Thromb Haemost 2023; 21 (8): 2064–2077. doi: 10.1016/j.jtha.2023.03.029.

41. Graves SM, Montemorano L, Rood KM et al. Viscoelastic testing in an obstetric population at high risk of hemorrhage. Am J Perinatol 2024; 41 (7): 915–923. doi: 10.1055/a-1788-5025.

42. Perelman AD, Limaye M, Blakemore J et al. Thromboelastography versus standard coagulation assays in patients with postpartum hemorrhage. Am J Perinatol 2024; 41 (S 01): e911–e916. doi: 10.1055/a-1974-5055.

43. De Robertis E, Kozek-Langenecker SA, Tufano R et al. Coagulopathy induced by acidosis, hypothermia and hypocalcaemia in severe bleeding. Minerva Anestesiol 2015; 81 (1): 65–75.

44. Ditzel RM, Anderson JL, Eisenhart WJ et al. A review of transfusion – and trauma-induced hypocalcemia: is it time to change the lethal triad to the lethal diamond? J Trauma Acute Care Surg 2020; 88 (3): 434–439. doi: 10.1097/TA.0000000000002570.

45. Schriner JB, Van Gent JM, Meledeo MA et al. Impact of transfused citrate on pathophysiology in massive transfusion. Crit Care Explor 2023; 5 (6): e0925. doi: 10.1097/CCE.000000000000925.

46. Erfani H, Shamshirsaz AA, Fox KA et al. Severe hypocalcemia during surgery for placenta accreta spectrum: the case for empiric replacement. Acta Obstet Gynecol Scand 2019; 98 (10): 1326–1331. doi: 10.1111/aogs.13636.

47. Epstein D, Solomon N, Korytny A et al. Association between ionised calcium and severity of postpartum haemorrhage: a retrospective cohort study. Br J Anaesth 2021; 126 (5): 1022–1028. doi: 10.1016/j.bja.2020.11.020.

48. Hofer S, Blaha J, Collins PW et al. Haemostatic support in postpartum haemorrhage: a review of the literature and expert opinion. Eur J Anaesthesiol 2023; 40 (1): 29–38. doi: 10.1097/EJA.0000000000001744.

49. Ducloy-Bouthors AS, Mercier FJ, Grouin JM et al. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG 2021; 128 (11): 1814–1823. doi: 10.1111/1471-0528. 16699.

50. Lier H, Annecke T, Girard T et al. Peripartum haemorrhage: haemostatic aspects of the updated peripartum haemorrhage guideline of the German-speaking countries. Transfus Med Hemother 2023; 50 (6): 547–558. doi: 10.1159/000530659.

51. de Lloyd L, Jenkins PV, Bell SF et al. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. J Thromb Haemost 2023; 21 (4): 862–879. doi: 10.1016/j.jtha.2022.11.036.

52. Bouthors AS. Crucial new insights into the understanding and treatment of acute obstetric coagulopathy. J Thromb Haemost 2023; 21 (4): 779. doi: 10.1016/j.jtha.2022.12.010.

53. Bell SF, de Lloyd L, Preston N et al. Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays. J Thromb Haemost 2023; 21 (8): 2064–2077. doi: 10.1016/j.jtha.2023.03.029.

54. Collins P, Abdul-Kadir R, Thachil J. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (1): 205–210. doi: 10.1111/jth.13174.

55. Surbek D, Blatný J, Wielgos M et al. Role of recombinant factor VIIa in the clinical management of severe postpartum hemorrhage: consensus among European experts. J Matern Fetal Neonatal Med 2024; 37 (1): 2332794. doi: 10.1080/14767058.2024.2332794.

56. Cines DB, Levine LD. Thrombocytopenia in pregnancy. Hematol Am Soc Hematol Educ Program 2017; 2017 (1): 144–151. doi: 10.1182/asheducation-2017.1.144.

57. Practice Bulletin No. 166: Thrombocytopenia in pregnancy. Obstet Gynecol 2016; 128 (3): e43–e53. doi: 10.1097/AOG.00000000000 01641.

58. Estcourt LJ, Malouf R, Doree C et al. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. Cochrane database Syst Rev 2018; 9 (9): CD012779. doi: 10.1002/14651858.CD012779.pub2.

59. Wang L, Zhong J, Xiao D et al. Thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-a2-plasmininhibitor complex (PIC), and tissue plasminogen activator-inhibitor complex (t-PAIC) assessment of fibrinolytic activity in postpartum hemorrhage: a retrospective comparative cohort study. Ann Transl Med 2022; 10 (23): 1273. doi: 10.21037/atm-22-5221.

60. Middeldorp S, Naue C, Köhler C. Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom? Hamostaseologie 2022; 42 (1): 54–64. doi: 10.1055/a-1717- 7663.

61. Erez O, Othman M, Rabinovich A et al. DIC in pregnancy – pathophysiology, clinical characteristics, diagnostic scores, and treatments. J Blood Med J Blood Med 2022; 13: 21–44. doi: 10.2147/JBM.S273047.

62. Squizzato A, Gallo A, Levi M et al. Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC subcommittees on disseminated intravascular coagulation and perioperative and critical care thrombosis and hemostasis. J Thromb Haemost 2020; 18 (9): 2400–2407. doi: 10.1111/jth. 14946.

63. Iba T, Saitoh D, Wada H et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 2014; 18 (5): 497. doi: 10.1186/s13054-014-0497-x.

64. Yatabe T, Inoue S, Sakamoto S et al. The anticoagulant treatment for sepsis induced disseminated intravascular coagulation; network meta-analysis. Thromb Res 2018; 171: 136–142. doi: 10.1016/j.thromres.2018.10.007.

65. Allingstrup M, Wetterslev J, Ravn FB et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2016; 2 (2): CD005370. doi: 10.1002/14651858.CD005370.pub3.

66. Rodgers GM, Mahajerin A. Antithrombin therapy: current state and future outlook. Clin Appl Thromb Hemost 2023; 29. 10760296231205279. doi: 10.1177/10760296231205279.

67. Tagami T. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: re-evaluation of a ‘pendulum effect’ drug using a nationwide database. J Thromb Haemost 2018; 16 (3): 458–461. doi: 10.1111/jth.13948.

68. Allingstrup M, Wetterslev J, Ravn FB et al. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med Intensive Care Med 2016; 42 (4): 505–520. doi: 10.1007/s00134-016-4225-7.

69. Ryu T, Kurokawa Y, Hirayu N et al. Resuscitative endovascular balloon occlusion of the aorta: a novel approach for treating amniotic fluid embolism with disseminated intravascular coagulopathy – a report of two cases. J Obstet Gynaecol Res 2024; 50 (9): 1722–1727. doi: 10.1111/jog.16007.

70. Metodika CRediT (Contributor Roles Taxonomy). 2024 [online]. Available from: https: //www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-statement.

Doručeno/Submitted: 18. 11. 2024

Přijato/Accepted: 18. 11. 2024

prof. MUDr. Antonín Pařízek, CSc.

Perinatologické centrum

Klinika gynekologie, porodnictví a neonatologie

1. LF UK a VFN v Praze

Apolinářská 18

128 51 Praha 2

parizek@porodnice.cz

Seznam zkratek

ACCORD – ACcurate COnsensus Reporting Document

aPTT – aktivovaný parciální tromboplastinový čas